With Qarziba Inj (dinutuximab beta, Recordati Korea), the first drug that has been applied the approval-evaluation-negotiation pilot project, passing the Health Insurance Review and Assessment Service's Drug Reimbursement Evaluation Committee, the drug price negotiation for the drug is also expected to progress quickly.

However, the drug’s post-listing management is expected to be key rather than the speed of approval.

Qarziba was recognized as adequate for reimbursement at the 10th Drug Reimbursement Evaluation Committee (DREC) meeting in 2024 that was held on the 10th of this month. The committee had made a non-reimbursement decision in August, but after reconsideration, the drug pas